KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cme (CME) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Cme (CME) over the last 17 years, with Q3 2025 value amounting to $2.49.

  • Cme's EPS (Weighted Average and Diluted) fell 40.0% to $2.49 in Q3 2025 from the same period last year, while for Sep 2025 it was $10.32, marking a year-over-year increase of 851.74%. This contributed to the annual value of $9.67 for FY2024, which is 915.39% up from last year.
  • Cme's EPS (Weighted Average and Diluted) amounted to $2.49 in Q3 2025, which was down 40.0% from $2.81 recorded in Q2 2025.
  • Cme's 5-year EPS (Weighted Average and Diluted) high stood at $2.81 for Q2 2025, and its period low was $1.42 during Q2 2021.
  • Over the past 5 years, Cme's median EPS (Weighted Average and Diluted) value was $2.24 (recorded in 2023), while the average stood at $2.17.
  • As far as peak fluctuations go, Cme's EPS (Weighted Average and Diluted) surged by 12434.78% in 2021, and later tumbled by 2751.94% in 2022.
  • Cme's EPS (Weighted Average and Diluted) (Quarter) stood at $1.69 in 2021, then grew by 4.14% to $1.76 in 2022, then rose by 27.12% to $2.24 in 2023, then grew by 7.25% to $2.4 in 2024, then grew by 3.77% to $2.49 in 2025.
  • Its EPS (Weighted Average and Diluted) was $2.49 in Q3 2025, compared to $2.81 in Q2 2025 and $2.62 in Q1 2025.